Overview
On 17 October 2019, orphan designation EU/3/19/2211 was granted by the European Commission to Therapharm Deutschland GmbH, Germany, for besilesomab for treatment in haematopoietic stem cell transplantation.
Key facts
Active substance |
besilesomab
|
Intended use |
Treatment in haematopoietic stem cell transplantation
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/19/2211
|
Date of designation |
17/10/2019
|
Sponsor |
Telix Innovations |
Update history
Date | Update |
---|---|
December 2022 | The sponsor’s name was changed from Advanced Nuclear Medicine Ingredients to Telix Innovations. |
October 2021 | The sponsorship was transferred to Advanced Nuclear Medicine Ingredients, Belgium. |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: